Phone orders: 888-838-5231

Back Benfotiamine - 200mg, 30 capsules

Brand: Terraternal

FREE SHIPPING INCLUDED

Also available:

 
 

The results of benfotiamine studies from around the globe have been pouring in over the last decade with remarkable results. They have offered a new hope in the prevention and even reversal in some cases of the devastating damage in the body that is the result of the glycation, particularly to the nervous system.

A More Bioavailable Version of Thiamine

A number of in vitro studies showed that when Thiamine (B1) was applied directly to cells in culture that had been exposed to high glucose levels, it significantly reduced total AGE formation, increased cell survival and restored reproductive activity to normal levels.1

But B1 is not fat soluble so has poor bioavailability when taken orally. Above a low threshold, additional consumed B1 is simply excreted in urine.2 Benfotiamine is Thiamin’s fat-soluble cousin, and is much more able to penetrate the fatty-acid-rich cell membranes. One study showed it has a 420% better overall bioavilability (420% more of the supplement was recovered in cell plasma) than Thiamine3 as a result. Also, another study showed a 120-fold increase in TDP levels (thiamine diphosphate - the conjugated form that both B1 and BFT become in the body), when compared with Thiamine.4


An Inhibitor of Glycation and Supporter of Nerve Health

Because of this improved bioavailability, benfotiamine has been shown to inhibit intracellular AGE formation in real human subjects in a way that is markedly superior to Thiamine.5 In one study in particular, the levels of two key AGE molecules(CML and Methlyglyoxal-derived AGEs) in red blood cells dropped an amazing 40% and 69% respectively after only 4 weeks of treatment.6

More exciting than the direct measurements of glycation is that we are also seeing these glycation reduction numbers borne out in the real experiences of human subjects of in vivo studies. Benfotiamine supplementation has greatly reduced neuropathy pain in humans (8.2 to 2.5 on a subjective assessment scale) with increased vibration perception dramatically increased nerve conduction velocity, restored normal blood vessel relaxation and accelerated pressure sore healing, improved kidney function, heart cell function and more.


Conclusion

Of all the supplements we offer to combat glycation, brought on by both elevated glucose levels and regular aging over time benfotiamine is the most promising. It is the centerpiece of our Glycation Guard product and today represents the most exciting potential in the supplement industry for glycation prevention and treatment.

Money Back Guarantee

If for any reason you are unsatisfied with a Terraternal product, simply return the unused portion to us within 30 days for a full refund. No questions asked.

Product Code: TRB001
Package Quantity: 30 capsules
Shipping Weight: 0.0000 lbs
Serving Size: 1 capsule
 

Benfotiamine Supplement Facts


 Supplement Amount Per Serving % Daily Value
 Benfotiamine 200 mg †
 † Daily Value not established  
   



References:

  • 1.
    La Selva M, Beltramo E, Pagnozzi F, et al. Thiamine corrects delayed replication and decreases production of lactate and advanced glycation end-products in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia. 1996 Nov;39(11):1263-8.

    Ahmed N, Luthen R, Haussinger D, et al. Increased protein glycation in cirrhosis and therapeutic strategies to prevent it. Ann NY Acad Sci. 2005 Jun;1043:718-24.

    Shangari N, Mehta R, O’brien PJ. Hepatocyte susceptibility to glyoxal is dependent on cell thiamin content. Chem Biol Interact. 2007 Jan 30;165(2):146-54.
  • 2.
    Geyer J, Netzel M, Bitsch I, et al. Bioavailability of water- and lipid-soluble thiamin compounds in broiler chickens. Int J Vitam Nutr Res. 2000 Dec;70(6):311-6.

    Hilbig R, Rahmann H. Comparative autoradiographic investigations on the tissue distribution of benfotiamine versus thiamine in mice. Arzneimittelforschung. 1998 May;48(5):461-8.
  • 3.
    Frank T, Bitsch R, Maiwald J, Stein G. Alteration of thiamine pharmacokinetics by end-stage renal disease (ESRD). Int J Clin Pharmacol Ther. 1999 Sep;37(9):449-55.

    Greb A, Bitsch R. Comparative bioavailability of various thiamine derivatives after oral administration. Int J Clin Pharmacol Ther. 1998 Apr;36(4):216-21.

  • 4.
    Frank T et al. High thiamine diphosphate concentrations in erythrocytes can be achieved in dialysis patients by oral administration of benfotiamine. Eur J Clin Pharmacol. 2000 Jun; 56(3):251-5.
  • 5.
    Lin J et al. Benfotiamine inhibits intracellular formation of advanced glycation end products in vivo. Diab. 2000, 49 (suppl 1): A143.
  • 6.
    Lin J et al. Benfotiamine inhibits intracellular formation of advanced glycation end products in vivo. Diab. 2000, 49 (suppl 1): A143.